Ivermectin beat metronidazole in the biggest head-to-head trial, 84.9 percent to 75.4 percent clear or almost clear at week 16. Then a split-face trial in people with almost no mites found the two drugs did the same thing to redness. Both results are true, and together they tell you more than either does alone. This is the ivermectin vs metronidazole question, answered from the trials instead of from habit.
Quick answer
In the ivermectin vs metronidazole comparison, the largest head-to-head trial found that topical ivermectin 1% cream cleared or nearly cleared more papulopustular rosacea than metronidazole 0.75% cream at week 16 (84.9% vs 75.4%). A July 2026 network meta-analysis of 32 trials agrees on lesion counts. But about two in three patients relapsed within 36 weeks in both arms, and when mite counts were near zero the two drugs performed alike on redness. A small 2026 study found that protruding follicular plugs on dermoscopy predicted a strong response to ivermectin but not to metronidazole.
Ivermectin vs metronidazole: the head-to-head trial everyone cites
The trial behind most ivermectin vs metronidazole claims is ATTRACT. About 960 adults with moderate to severe papulopustular rosacea were randomized to ivermectin 1% cream once daily or metronidazole 0.75% cream twice daily for 16 weeks, with an investigator who did not know which was which. At week 16, 84.9 percent of the ivermectin group were clear or almost clear, against 75.4 percent on metronidazole. Inflammatory lesion counts fell by 83.0 percent and 73.7 percent.[1] The gap opened early, from about the third week.
Tolerability was similar and low in both arms. Related skin adverse events occurred in 1.9 percent on ivermectin and 2.5 percent on metronidazole, and more patients found the metronidazole product irritating.[1] That is a real advantage, but a modest one.
Two limits matter. Ivermectin has only been tested in moderate to severe papulopustular rosacea, so extending the result to mild disease is extrapolation.[3] And the trial counted bumps. It says less about redness, which is what most people actually complain about.
The pooled evidence on ivermectin vs metronidazole, updated July 2026
In July 2026, JAMA Dermatology published a network meta-analysis of 32 randomized trials covering 11,399 adults and 10 topical treatments for moderate to severe rosacea. Compared with metronidazole, ivermectin reduced lesion counts more (mean difference 4.17, 95 percent CI 1.85 to 6.48) and so did encapsulated benzoyl peroxide (4.14, CI 0.62 to 7.66). Both also had higher investigator global assessment success (mean differences 10.31 and 15.51). Discontinuation for adverse events was similar across treatments, though encapsulated benzoyl peroxide was stopped more often than metronidazole.[4]
Earlier reviews point the same way. Ebbelaar and colleagues report a higher likelihood of success for ivermectin than metronidazole 0.75% cream at 12 weeks (relative risk 1.17, CI 1.08 to 1.29) and a larger reduction in lesion count (difference of 9.92 lesions).[3] If you want the full story on the benzoyl peroxide result, our benzoyl peroxide for rosacea guide covers what the microcapsule changed and what it never touches.
Not every pooled analysis ranks them the same. A 2024 network meta-analysis of minocycline, metronidazole, ivermectin and azelaic acid in moderate to severe disease found azelaic acid 15 percent, metronidazole 0.75 percent and ivermectin 1 percent had comparable effect sizes, and suggested azelaic acid 20 percent as the most effective topical.[5] Different trial sets, time points and outcomes produce different rankings. The safe reading is that ivermectin holds a modest edge on lesion counts in most analyses, and that none of them settles the question for redness.
Relapse: the number that should change the conversation
Ivermectin vs metronidazole looks like a two-way contest, but here is what the head-to-head headline hides. In the 36-week extension of the same trial, about two in three patients relapsed after stopping treatment, 62.7 percent and 68.4 percent in the two arms, which land within six points of each other. Median time to first relapse was 115 days after ivermectin and 85 days after metronidazole.[2]
Ebbelaar’s review is direct about the implication. The benefit of ivermectin’s acaricidal action in preventing relapse, compared with anti-inflammatory approaches, remains to be proven in a randomized trial.[3] A prospective study followed mite remission and relapse over time after ivermectin and reported that both remission of infestation and clinical remission were sustained for a long period.[8] That is encouraging, and it is not a controlled comparison.
So the choice between the two is a choice about the first three months, not about a cure. Plan the maintenance step before you finish the induction step. The oral options do not escape relapse either, as our isotretinoin for rosacea guide shows.
Ivermectin vs metronidazole when the mite count is near zero
The most useful trial for anyone with a negative mite test is a small one. Yeh and colleagues ran a rater-blinded, randomized, split-face trial in 27 people with erythematotelangiectatic rosacea and low Demodex counts. Mean density was 0.6 mites per cm2 by skin surface biopsy. One side of the face got ivermectin at bedtime, the other metronidazole twice daily, for three months.[6]
The blinded dermatologist saw no difference in persistent redness (change of -1.07 on the metronidazole side and -1.04 on the ivermectin side, p = 0.782). Both improved. Patients felt more improvement on the ivermectin side in erythema, warmth, itch and skin roughness by month 3, though their overall self-assessment did not differ (p = 0.17). Patients could tell the creams apart by texture and frequency, so those subjective results carry that bias.[6]
The reading the authors offer is the obvious one. If both drugs improve redness when almost no mites are present, the effect cannot depend mainly on killing mites. Both must be doing something anti-inflammatory. For ivermectin that idea has independent support from a model of allergic skin inflammation.[9] It also fits a wider pattern in rosacea therapy: several of the drugs work mainly on inflammation, and the mite matters most in a specific subset.
The dermoscopy sign that predicted who needed ivermectin vs metronidazole
That subset may be identifiable. In a 2026 prospective observational study, 23 adults with moderate to severe papulopustular rosacea used ivermectin 1% cream (10 patients) or metronidazole 1% gel (13 patients) once daily for 8 weeks. Treatment was chosen by the physician, not randomized. Blinded assessors scored lesion counts and dermoscopy.[7]
Both drugs significantly reduced inflammatory lesions. Any response occurred in 70 percent on ivermectin and 62 percent on metronidazole. Optimal response, more than 75 percent lesion reduction, occurred in 50 percent and 31 percent. Then the split: every ivermectin patient who reached optimal response had protruding follicular plugs at baseline, 5 of 5, and none of the five without plugs did (p = 0.004). Protruding follicular plugs are the yellowish keratotic concretions emerging from follicle openings, often called Demodex tails.[7]
On metronidazole the picture reversed. All four optimal responders had no plugs, and all four patients who did have plugs showed minimal or no response, though with numbers this small that was not statistically significant (p = 0.176). In the ivermectin group, disappearance of the plugs after therapy went with excellent clinical improvement.[7]
Read this with discipline. It is 23 people, not randomized, from one report. It is a signal that fits the mechanism, not a rule. But it is the first reported dermoscopic predictor of which of these two drugs a patient may need, and dermoscopy is quick and cheap. Finding the subset where the mite matters is the skill. For the eye version of the same problem, see our ocular rosacea guide.
Why the two are not interchangeable in theory
The mainstream reading is that metronidazole is anti-inflammatory and possibly antibacterial. In vitro work points to an effect on neutrophil function rather than direct scavenging of reactive oxygen species.[12] Several reviews describe it as having only anti-inflammatory effects, not acaricidal ones.[10] The 2026 dermoscopy paper says it is not known to have significant acaricidal effects on Demodex.[7] Some older reports credit it with antiparasitic activity, and a retrospective study of oral metronidazole add-on therapy framed its mechanism as both anti-inflammatory and anti-Demodex.[11] The evidence for a real acaricidal effect is thin.
Ivermectin acts on glutamate-gated chloride channels in the mite and has its own anti-inflammatory action. That dual mechanism is why it is described as the more etiological option, and why the relapse question above is the one that would settle the matter.
How to use the ivermectin vs metronidazole evidence if you are choosing
This is education, not a prescription. It is what the ivermectin vs metronidazole evidence supports for a conversation with your clinician.
- Bumps with plugs or gritty follicles, moderate to severe: the evidence leans toward ivermectin, and dermoscopy may help confirm the pattern.
- Mostly redness with few bumps: both are modest. Tolerance, cost and how many times a day you will actually apply it decide.
- Frequency is part of the comparison. In the trials ivermectin cream was applied once daily and metronidazole 0.75% cream twice daily, so the drug you will actually apply consistently matters as much as the drug on paper.
- Judge at 12 to 16 weeks. The trials read outcomes at 12 and 16 weeks. Switching at week 4 tells you nothing.
- Plan for relapse. Ask what the maintenance step is before you finish the induction step.
- Consider the alternatives. Azelaic acid and encapsulated benzoyl peroxide performed well in the pooled analyses[4][5]. The benzoyl peroxide guide covers the trade-offs.
- Eyes need their own plan. Neither cream is a lid margin treatment. Eye symptoms belong with an eye specialist, and our ocular rosacea guide explains why.
If your rosacea began after a course of facial steroids, or after starting a biologic, the mite may be a bigger part of the story. Our steroid induced rosacea guide and our dupilumab facial redness guide cover those two situations.
What nobody knows yet
The ivermectin vs metronidazole literature is strong on lesion counts and thin on almost everything else. Here is where it runs out.
- No trial has shown that ivermectin’s acaricidal action prevents relapse better than an anti-inflammatory approach.
- The plug predictor comes from 23 non-randomized patients in one report and needs replication.
- Redness is measured far less often than lesion counts, so the evidence is thinnest on the complaint people care about most.
- Mild disease is barely represented in the ivermectin trials.
- Combination and sequencing of the two drugs is not settled by these head-to-head designs, which compared them rather than layered them.
The bottom line on ivermectin vs metronidazole
Ivermectin has a modest, consistent edge on inflammatory lesions in most head-to-head and pooled analyses. Metronidazole remains a real, well-tolerated option, and on redness with low mite counts the two look alike. Neither prevents relapse reliably, so the maintenance plan matters as much as the first choice. And for the subset of patients with plugs on dermoscopy, a small 2026 signal suggests the mite-directed drug is the one to try first. Ask for the evidence behind the choice, not just the prescription.
For practitioners
Baseline before you choose. Record lesion counts, investigator global assessment, clinician erythema grade, and a mite density by skin surface biopsy or a dermoscopy note on protruding follicular plugs. You need something to compare at week 12.
Dermoscopy is cheap. The 2026 predictor study[7] suggests plugs favor ivermectin. It is hypothesis-generating, non-randomized, and small. Use it to inform, not to withhold either drug.
Scope. ATTRACT enrolled moderate to severe papulopustular disease[1][3]. For mild or predominantly erythematous rosacea, the low-density trial[6] suggests either agent improves redness, with subjective advantages to ivermectin that carry a blinding caveat.
Ranking is design-dependent. When you quote ivermectin vs metronidazole, say which analysis you mean. The 2026 network meta-analysis[4] favors ivermectin and encapsulated benzoyl peroxide over metronidazole on lesion counts. The 2024 network meta-analysis[5] found comparable effects for ivermectin, metronidazole and azelaic acid 15 percent. Say which one you are quoting.
Relapse counselling. Set expectations at the first visit. About two in three relapse within 36 weeks of stopping either agent[2]. Plan maintenance, and discuss when to escalate to an oral option.
Acaricidal claims. Avoid stating that ivermectin cures the mite problem in rosacea. The relapse benefit of acaricidal action is unproven in a randomized trial[3].
Frequently asked questions
Is ivermectin better than metronidazole for rosacea?
For inflammatory lesions, most analyses say ivermectin holds a modest edge, including the largest head-to-head trial (84.9% vs 75.4% clear or almost clear at week 16) and a July 2026 network meta-analysis[1][4]. For redness, and when mite counts are very low, the two behave alike[6].
How long before either one works?
In the head-to-head trial the gap between the drugs opened from about week 3, but outcomes were judged at 12 to 16 weeks[1]. Give either drug a full course before deciding it has failed.
Can I use both together?
The head-to-head trials compared them, they did not combine them. Whether to layer them, sequence them or switch is a clinician’s decision, based on your pattern, tolerance and how you respond.
Does a negative Demodex test mean ivermectin will not work?
No. In a split-face trial of people with low mite counts, both drugs improved persistent redness equally by the blinded assessment[6]. A negative test removes the acaricidal argument, not the possibility of benefit. Remember that a single sample can miss mites, which our rosacea types guide touches on when it explains why diagnosis is now by phenotype.
What does the ivermectin vs metronidazole evidence say about mostly redness rosacea?
Very little, because the big trials counted bumps. The one trial built for low mite counts found both drugs improved persistent redness equally by the blinded assessment[6]. If redness is your main complaint, other tools such as light-based treatment may be part of the plan, as our IPL for rosacea guide explains.
Why did my rosacea come back after I stopped?
Because that is what usually happens. About two in three patients relapsed within 36 weeks of stopping either drug[2]. Relapse is the norm, so a maintenance plan is part of treatment, not an afterthought.
Which is gentler on the skin?
In the head-to-head trial related skin events were low in both arms (1.9% and 2.5%), and more patients found metronidazole irritating[1]. Individual tolerance varies with the vehicle, so tell your clinician early if either stings.
References
- Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 2015;172(4):1103-1110.
- Taieb A, et al; Ivermectin Phase III Study Group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. Br J Dermatol 2016. PMID 26691278.
- Ebbelaar CCF, Venema AW, Van Dijk MR. Topical ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations. Dermatol Ther (Heidelb) 2018 (online 25 June). PMC6109029.
- Amstutz AV, et al. Topical preparations for moderate to severe rosacea treatment: a systematic review and network meta-analysis. JAMA Dermatol 2026 (online 1 July). doi 10.1001/jamadermatol.2026.2062. Source
- The efficacy and safety of minocycline, metronidazole, ivermectin, and azelaic acid in moderate-to-severe papulopustular rosacea: a systematic review and network meta-analysis. JAAD Int 2024, doi 10.1016/j.jdin.2023.12.010. PMC11979399. Source
- Yeh MC, Tsai J, Huang YC, Wang HH. Topical metronidazole versus ivermectin for low-density Demodex rosacea: a rater-blinded, randomized, split-face trial. Acta Derm Venereol 2022;102:adv00811. PMID 36317858. Source
- Dermoscopic response predictors in papulopustular rosacea treated with topical ivermectin and metronidazole: a prospective observational comparative study. Clin Cosmet Investig Dermatol 2026;19. PMID 41716253. doi 10.2147/CCID.S589715. Source
- Trave I, et al. Papulopustular rosacea treated with ivermectin 1% cream: remission of the Demodex mite infestation over time and evaluation of clinical relapses. Dermatol Pract Concept 2022;12(4). PMID 36534532.
- Ventre E, Rozieres A, Lenief V, et al. Topical ivermectin improves allergic skin inflammation. Allergy 2017;72:1212-1221.
- Evidence for the clinical association between Demodex and rosacea: a review. Dermatology 2024;240(1). Karger.
- Maintenance of remission after oral metronidazole add-on therapy in rosacea treatment: a retrospective, comparative study. Ann Dermatol 2022. PMC9763916.
- In vitro study of the effect of metronidazole on reactive oxygen species generation in neutrophil and xanthine-xanthine oxidase systems, in the context of rosacea. PMID 2936372.
Next steps: Take the Demodex quiz | Find a practitioner | Browse the research hub
About the author. Marina Ivakhnenko is a functional skin practitioner and the editor of demodex.net/. This article is educational and is not a substitute for medical care. If you are on prescription treatment, do not change it without your prescriber.